ES8203225A1 - Procedimiento para aislar antigenos glicoproteicos de un vi-rus - Google Patents

Procedimiento para aislar antigenos glicoproteicos de un vi-rus

Info

Publication number
ES8203225A1
ES8203225A1 ES502549A ES502549A ES8203225A1 ES 8203225 A1 ES8203225 A1 ES 8203225A1 ES 502549 A ES502549 A ES 502549A ES 502549 A ES502549 A ES 502549A ES 8203225 A1 ES8203225 A1 ES 8203225A1
Authority
ES
Spain
Prior art keywords
vaccines
preparation
glycoproteic
antigens
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES502549A
Other languages
English (en)
Spanish (es)
Other versions
ES502549A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Publication of ES502549A0 publication Critical patent/ES502549A0/es
Publication of ES8203225A1 publication Critical patent/ES8203225A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES502549A 1980-06-05 1981-05-27 Procedimiento para aislar antigenos glicoproteicos de un vi-rus Expired ES8203225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8012522A FR2483779A1 (fr) 1980-06-05 1980-06-05 Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins

Publications (2)

Publication Number Publication Date
ES502549A0 ES502549A0 (es) 1982-04-01
ES8203225A1 true ES8203225A1 (es) 1982-04-01

Family

ID=9242745

Family Applications (1)

Application Number Title Priority Date Filing Date
ES502549A Expired ES8203225A1 (es) 1980-06-05 1981-05-27 Procedimiento para aislar antigenos glicoproteicos de un vi-rus

Country Status (19)

Country Link
US (1) US4344935A (enExample)
EP (1) EP0041880B1 (enExample)
JP (1) JPS5726624A (enExample)
AR (1) AR228865A1 (enExample)
AT (1) ATE3239T1 (enExample)
AU (1) AU546088B2 (enExample)
CA (1) CA1174598A (enExample)
DE (1) DE3160264D1 (enExample)
DK (1) DK228081A (enExample)
ES (1) ES8203225A1 (enExample)
FI (1) FI811685A7 (enExample)
FR (1) FR2483779A1 (enExample)
GR (1) GR74610B (enExample)
IE (1) IE51226B1 (enExample)
IL (1) IL62913A (enExample)
NO (1) NO811873L (enExample)
NZ (1) NZ197306A (enExample)
PT (1) PT73032B (enExample)
ZA (1) ZA813479B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721675A (en) * 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
US4645666A (en) * 1982-06-08 1987-02-24 The Regents Of The University Of California Vaccine for bluetongue disease employing platinum compounds
GB8502096D0 (en) * 1985-01-28 1985-02-27 Medical Res Council Influenza vaccine
NZ224422A (en) * 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US4909940A (en) * 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
US4975119A (en) * 1989-04-25 1990-12-04 Rheox, Inc. Liquid antisettling agents for organic coating compositions
FR2671974A1 (fr) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.
US5741493A (en) * 1991-01-24 1998-04-21 Pasteur Merieux Serums Et Vaccins Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
US6780630B1 (en) * 1992-07-10 2004-08-24 Baylor College Of Medicine Parenteral immunization against rotavirus
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
WO1997000088A2 (en) 1995-06-14 1997-01-03 Baylor College Of Medicine Rotavirus enterotoxin nsp4 and methods of using same
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
DE19938767C2 (de) * 1999-08-16 2002-10-24 Tad Pharma Gmbh Spaltimpfstoffe

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE661402A (enExample) 1964-03-20
US3847737A (en) * 1965-03-22 1974-11-12 A Kanarek Inactivation of myxoviruses and method of preparing a vaccine therefrom
US3629470A (en) * 1968-04-08 1971-12-21 Burroughs Wellcome Co Process for purification of animal rna viruses
BR6915288D0 (pt) * 1969-03-15 1973-02-08 Bayer Ag Processo para a purificacao de solucoes do virus da febre aftosa
US3989818A (en) * 1970-08-14 1976-11-02 South African Inventions Development Corporation Influenza virus vaccine
US3790552A (en) * 1972-03-16 1974-02-05 Us Health Method of removing hepatitis-associated antigen from a protein fraction using polyethylene glycol
US3962421A (en) * 1973-06-18 1976-06-08 American Home Products Corporation Method for the disruption of lipid-containing viruses
GB1486557A (en) 1973-10-18 1977-09-21 Flockhart & Co Process for the preparation of pyrogen-free sub-unit vaccine
US3951937A (en) * 1973-12-20 1976-04-20 The Community Blood Council Of Greater New York, Inc. Large scale purification of hepatitis type B antigen using polyethylene glycol
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
AU507149B2 (en) 1975-01-16 1980-02-07 Mount Sinai School Of Medicine Of The City University Of New York, The Method of influenza immunization
FR2422720A2 (fr) 1977-04-26 1979-11-09 Elf Aquitaine Separation et purification de proteines par chromatographie
FI66020C (fi) * 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
DE2750045A1 (de) * 1977-11-09 1979-05-10 Behringwerke Ag Verfahren zur entfernung von detergentien aus virusantigensuspensionen

Also Published As

Publication number Publication date
JPS5726624A (en) 1982-02-12
ATE3239T1 (de) 1983-05-15
DK228081A (da) 1981-12-06
NZ197306A (en) 1984-03-16
FI811685L (fi) 1981-12-06
ES502549A0 (es) 1982-04-01
FI811685A7 (fi) 1981-12-06
US4344935A (en) 1982-08-17
DE3160264D1 (en) 1983-06-16
NO811873L (no) 1981-12-07
EP0041880A1 (fr) 1981-12-16
PT73032A (fr) 1981-06-01
AU546088B2 (en) 1985-08-15
AU7117081A (en) 1981-12-10
IL62913A0 (en) 1981-07-31
ZA813479B (en) 1982-06-30
AR228865A1 (es) 1983-04-29
FR2483779A1 (fr) 1981-12-11
FR2483779B1 (enExample) 1983-07-22
EP0041880B1 (fr) 1983-05-11
GR74610B (enExample) 1984-06-29
IL62913A (en) 1984-08-31
CA1174598A (en) 1984-09-18
PT73032B (fr) 1982-07-01
IE51226B1 (en) 1986-11-12
IE811168L (en) 1981-12-05

Similar Documents

Publication Publication Date Title
ES8203225A1 (es) Procedimiento para aislar antigenos glicoproteicos de un vi-rus
Rustigian Persistent infection of cells in culture by measles virus I. Development and characteristics of HeLa sublines persistently infected with complete virus
IT1041469B (it) Apparecchio per effettuare l operazione di plasmaferesi con separazione di globuli rossi del plasma contemporanea all estrazione del sangue del donatore
ES8203224A1 (es) Procedimiento de preparacion de globulos rojos concentrados para almacenamiento.
ES8100885A1 (es) Procedimiento y sistema para separar componentes sanguineos contenidos en una muestra de sangre
IT1093222B (it) Provetta di separazione per la separazione mediante centrifugazione
ES305662A1 (es) Procedimiento y aparato para la concentracion por congelacion de los comestibles acuosos.
ES8200816A1 (es) Un metodo para recuperar neoantigeno celular asociado con celulas infectadas con virus.
FI850051L (fi) Virusantigen, foerfarande foer dess tillvaratagning och anvaendning vid diagnos och terapi.
DK413388D0 (da) Fremgangsmaade til rensning af olivenolie
CO4480040A1 (es) Proceso de purificacion del antigeno de superficie viral hepatitis b que comprende el peptido pres 2
Laude Improved method for the purification of hog cholera virus grown in tissue culture
Judge et al. Ultrastructure of Trypanosoma lewisi
Parks et al. Buoyant density of bovine viral diarrhea virus
Hewicker et al. Kidney lesions in cattle persistently infected with bovine viral diarrhoea virus
GB1036205A (en) Process for the separation of the products obtained through the nitration of cyclohexane in gaseous phase
Culliford Haptoglobins and transferrins in forensic bloodstains
GB1209272A (en) Cleaning of phosphoric acid
ES2058240T3 (es) Nuevos peptidos sinteticos inmunologicamente activos utiles para la preparacion de una vacuna antimalarica.
ES2050343T3 (es) Procedimiento para la purificacion de tereftalato de dimetilo.
SU126497A1 (ru) Способ получени 2-метокси-6, 9-дихлор-7-нитроакридина
DK128147B (da) Fremgangsmåde til fjernelse af acrinol fra en vandig, acrinolholdig opløsning af γ-globulin.
Karabatsos Density gradient characterization of disrupted and untreated eastern encephalitis virus
Rubinstein et al. Isolation of a cytoplasmic polyhedrosis virus by physical and immunological techniques
SU950394A1 (ru) Способ получени убихинона